ArticleTissue engineering and regenerative medicine2025
Tonsil-Derived Mesenchymal Stem Cell-Derived Small Extracellular Vesicles (sEVs) Restore Myo-Inositol Production in LPS-Treated Skeletal Muscle.
Article in Tissue engineering and regenerative medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Non-Cytopathic Mammalian Orthoreovirus Infection Triggers Innate Immune Responses in Human Tonsil-Derived Mesenchymal Stem Cells: Implications for Cell Therapy Quality Control.Tissue engineering and regenerative medicine · 2026Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSystemic inflammation, often induced by elevated circulating lipopolysaccharide (LPS) levels, is a common consequence of intestinal epithelial barrier damage and microbial translocation. This condition is particularly prevalent in menopausal women, who are at increased risk for chronic inflammation and metabolic syndrome due to physiological changes during menopause. Myo-inositol has been shown to improve metabolic profiles in menopausal women with metabolic syndrome. In this study, we investigated whether small extracellular vesicles (sEVs) from human palatine tonsil-derived mesenchymal stem cells (T-MSCs) can restore circulating myo-inositol levels and promote myo-inositol synthesis in skeletal muscle under repeated LPS exposure, mimicking the intestinal leakage seen in menopausal women.
methodsOver 2 weeks period, LPS was repeatedly administered to mice, along with a group that also received T-MSC-derived sEVs. After 15 days, the expression of proteins involved in inositol synthesis in skeletal muscle, and serum inositol levels were measured. Additionally, intracellular inositol expression was compared in LPS-treated skeletal muscle cells with and without T-MSC sEVs treatment in vitro. Lastly, the protein and microRNA composition of T-MSC sEVs was analyzed.
resultsOur results demonstrated that T-MSC-derived sEVs significantly increased serum myo-inositol levels and enhanced the expression of myo-inositol synthesis proteins in mice exposed to LPS. Similarly, LPS-treated myotubes supplemented with T-MSC sEVs exhibited restored myo-inositol expression. Moreover, T-MSC sEVs were found to contain high levels of muscle-related proteins.
conclusionThese findings suggest that T-MSC sEVs may serve as a promising therapeutic strategy for mitigating the effects of intestinal leakage and chronic inflammation in menopausal women. By improving skeletal muscle mass and maintaining myo-inositol levels, T-MSC sEVs offer potential for addressing metabolic disturbances associated with menopause.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.